This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Pioneer in Dermatologic Research and Chemotherapy

AARON LICHTIN, Ph.G.; IRA LEO SCHAMBERG, M.D.

AMA Arch Derm. 1956;73(5):493-500.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Today the United States leads the world in pharmaceutical and chemical research and manufacturing. This preeminence has been gained only since World War I, through the imagination, initiative, and enterprise of many men. This is but an early chapter in the story of the fight for American independence of European countries in this field.

Of 592 drugs listed in the 1916 edition of New and Nonofficial Remedies,¹ 228 were imported into the United States from Germany. Among these were such products as Aspirin, Anesthesin (benzocaine), Salvarsan (arsphenamine), Neosalvarsan (neoarsphenamine), and Novocaine (procaine). The supply from Germany, the only source of many of these, was abruptly cut off by World War I. In 1919, Leech, Rabak, and Clark² stated: "Before European hostilities the United States was so dependent on Germany for synthetic drugs that the dependence was considered a necessity." Most Americans at that time . . . [Full Text PDF of this Article]

Author Affiliations
Philadelphia

Footnotes
Submitted for publication Jan. 3, 1956.

Visiting Lecturer, Graduate School of Medicine, University of Pennsylvania (Mr. Lichtin).

Assistant Professor of Dermatology, Graduate School of Medicine, University of Pennsylvania; Senior Attending Dermatologist, Albert Einstein Medical Center, Northern Division (Dr. Schamberg).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?